Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02094755 · ClinicalTrials.gov registry record
Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)
A clinical trial, sponsored by University of Southern California.
- Completed
- Registry status
- 100
- Enrollment target
NCT02094755 is a clinical trial that has completed, run by University of Southern California. The registered enrollment target is 100 participants.
The verdict
NCT02094755 has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a major cause of death and disability (secondary to myocardial infarction, stroke and amputation). The mortality in patients with CLI approaches 25% and 50% at one and five years respectively. High on-treatment platelet reactivity (HPR) in patients treated with aspirin and clopidogrel (previously referred to as "resistance") is associated with an increased risk of recurrent cardiovascular events after percutaneous coronary interventions and acute coronary syndromes. The prevalence and significance of High on-treatment Platelet Reactivity (HPR) in patients with critical limb ischemia treated with aspirin and/or clopidogrel is not known. The investigators project aims to investigate the prevalence of HPR (to aspirin and clopidogrel) in one hundred patients with diagnosis of critical limb ischemia encountered at University of Southern California (USC) affiliated hospitals (Los Angeles County Hospital and Keck Hospital of University of Southern California).
Interventions
- OTHER Blood draw only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-06-19 |
| Est. Completion | 2017-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02094755
The ClinicalTrials.gov registry entry for NCT02094755 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw only is the first listed.
NCT02094755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02094755 about?
NCT02094755 is a clinical study titled "Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)". Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a major cause of death and disability (secondary to myocardial infarction, stroke and amputation). The mortality in pat...
What is the current status of trial NCT02094755?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2013-06-19. Estimated completion is 2017-01-31.
What interventions are being tested in trial NCT02094755?
The interventions under investigation include: Blood draw only (OTHER).
Who is sponsoring clinical trial NCT02094755?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.